Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OXIRI in Advanced/Metastatic Pancreatic Adenocarcinoma
NCT02368860Phase 1Completed
- Sponsor
- National Cancer Centre Singapore
- Start
- Sep 2013
- Primary completion
- May 2020
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of oxaliplatin, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab and capecitabine in pancreatic adenocarcinoma (PDAC), sponsored by National Cancer Centre Singapore. Primary endpoint: Safety and tolerability of the OXIRI regimen. Started Sep 2013; status: completed.
02
Drugs
oxaliplatinirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabcapecitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02368860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02368860.